OncoSec Collaborates with Smart Patients to Form New Online Community for Patients

OncoSec Collaborates with Smart Patients to Form New Online Community for Patients

Co-Founded by Former Chief Health Strategist of Google

SAN DIEGO--(BUSINESS WIRE)-- OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors, is one of the first to partner with Smart Patients: a new online community where patients with life-threatening conditions who are looking for or participating in clinical trials can share their feedback and experiences. Google's former Chief Health Strategist, Roni Zeiger, will be speaking at the TEDMED conference in Washington, D.C. today to unveil the new website.

OncoSec is working with Smart Patients to create a community for Merkel cell carcinoma (MCC) patients. MCC is an extremely rare and aggressive form of skin cancer that currently has no approved therapies. OncoSec is conducting the only active Phase II immunotherapy trial that is focused specifically on the disease. The Smart Patients partnership will provide valuable insight from patients to help improve clinical trial design and enable better collaboration with patients.

"We're excited to be working with Dr. Zeiger, and to be a part of creating this valuable resource for the Merkel cell community," said OncoSec's CEO, Punit Dhillon. "One of the most frightening parts of being diagnosed with a rare disease like MCC is a lack of information about the condition and treatment options. Smart Patients is providing an important resource to help patients connect and learn from each other."

Roni Zeiger, co-founder and CEO of Smart Patients, noted, "Together with OncoSec, we will be able to gain a better understanding of MCC from a patient perspective, and help design more patient-centered trials that will make scientific breakthroughs for this disease available sooner."

About Smart Patients
Smart Patients is an online community for cancer patients and caregivers. The community includes a clinical trial search engine that presents trial data from ClinicalTrials.gov in a patient-friendly format. The community platform has been in private beta testing since January 2013 and is now open to all cancer patients and caregivers. To learn more, please visit us at www.smartpatients.com.

About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy, to treat solid tumors. ImmunoPulse and NeoPulse therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives. OncoSec Medical's core technology is based upon its proprietary use of an electroporation platform, to dramatically enhance the delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse). Treatment of various solid cancers, using these powerful and targeted anti-cancer agents, has demonstrated selective destruction of cancerous cells - while sparing healthy normal tissues - during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for ImmunoPulse, targeting lethal skin cancers. More information is available at http://www.oncosec.com/.

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Investor Relations:
OncoSec Medical Inc.
Amy Chan, 855-662-6732
investors@oncosec.com
or
Public Relations:
Dian Griesel Inc.
Laura Radocaj, 212-825-3210
lradocaj@dgicomm.com

KEYWORDS: United States North America California District of Columbia

INDUSTRY KEYWORDS:

The article OncoSec Collaborates with Smart Patients to Form New Online Community for Patients originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.